Anti-HBV Surface Antigen Polyclonal antibody

Introduction: Genome wide association study has identified chromosome 6p21.33 as a risk locus of hepatocellular carcinoma (HCC). MiR-877 is located on this region, functioning as a tumor suppressor. The aim of this study was to investigate the association between rs1264440 in the promoter of miR-877 and HCC risk. Materials and methods: A total of 352 HCC patients and 359 age, gender, ethnicity and living area matched controls were enrolled in this study. The rs1264440 was genotyped using the TaqMan allelic discrimination assay. MiR-877 expression in HCC tissues was examined using quantitative PCR. Results: After Adjustment for age, sex, smoking status, drinking status and HBsAg status, this study showed a significant association between the rs1264440 and HCC risk. Subjects with the rs1264440 TT genotype and T allele showed a 2.20- and 1.44-fold increased risk to develop HCC, respectively (TT vs. CC: 95% CI, 1.18-4.11, P=0.01; T vs. C: 95% CI, 1.07-1.94, P=0.02). The increased risk was also observed in smokers and nondrinkers subgroup. The rs1264440 TT carriers had lower levels of miR-877. Conclusion: The rs1264440 in the promoter region of miR-877 may regulate miR-877 expression and serve as an independent biomarker for the risk of HCC. (C) 2020 Elsevier Masson SAS. All rights reserved.

The present study aims to investigate an up-to-date prevalence of Hepatitis B Virus (HBV) infection among a mix population of Peshawar, Khyber Pakhtunkhwa, Pakistan. This study highlighted the relationship between HBV, demographic, clinical parameters and the risk factors in patients with HBV. A total of 4,758 blood samples from the mixed population were collected including 2382 male 2376 females. All the samples were subjected to hepatitis B surface antigen Immuno-chromatographic test (ICT), HBsAg enzyme-linked immunosorbent assay and by Reverse transcription polymerase chain reaction for the existence of antibodies against HBV. It was observed that 307 (12.8%) out of the 2382 individuals harbored antibodies in their blood against HBV. Among the different age groups, the highest number of incidences of HBV antibodies was found in the 16-25 age groups (7.01%). ICT positive samples were further screened by nested polymerase chain reaction (PCR) to determine the existence of active HBV-DNA. It was investigated that 5.7% (2382) of the total population (4758) tested was positive, among which the female 15.4% (367) possessed antibodies in their blood against HBV. Our results showed a higher male percentage than that of the female. The total HBV prevalence was recorded at 4.5% in all populations comprising both male and female. It was concluded that the highest prevalence of HBV was found in male and female in the age group 16-25, and then followed by the age group that lies between 26-55.